C. Becchimanzi

发表

Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high ‘life threat’ impact cardiopathy

F. Russo, L. Mastrullo, E. Morelli, 2011, British journal of haematology.

Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas

F. Russo, S. Lastoria, E. Morelli, 2011, European journal of haematology.

Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma

F. Russo, S. Lastoria, F. Frigeri, 2009, American journal of hematology.

Elevation of clonal serum free light chains in patients with HIV‐negative primary effusion lymphoma (PEL) and PEL‐like lymphoma

A. De Chiara, F. Frigeri, R. Di Francia, 2009, British journal of haematology.

RD‐CODOX‐M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B‐cell lymphoma

M. Saggese, F. Russo, A. De Chiara, 2012, British journal of haematology.

Abnormally Elevated Levels of Serum Free-Immunoglobulin Light Chains Are Frequently Found in Classic Hodgkin Lymphoma (cHL) and Predict Outcome of Patients with Early Stage Disease.

G. Castello, F. Russo, F. Frigeri, 2009 .

T cells from paroxysmal nocturnal haemoglobinuria (PNH) patients show an altered CD40‐dependent pathway

B. Rotoli, G. Terrazzano, M. Sica, 2005, Journal of leukocyte biology.

GPI‐defective monocytes from paroxysmal nocturnal hemoglobinuria patients show impaired in vitro dendritic cell differentiation

A. Masci, L. Racioppi, B. Rotoli, 2004, Journal of leukocyte biology.

Anti-PD1 Consolidation in Patients with Hodgkin Lymphoma at High Risk of Relapse after Autologous Stem Cell Transplantation: A Multicenter Real-Life Study

E. Derenzini, F. Morabito, E. Morelli, 2022, Cancers.

Glycosyl‐phosphatidyl‐inositol‐defective granulocytes from paroxysmal nocturnal haemoglobinuria patients show increased bacterial ingestion but reduced respiratory burst induction

B. Rotoli, G. Terrazzano, M. Sica, 2007, American journal of hematology.

DMSO-associated encephalopathy during autologous peripheral stem cell infusion: a predisposing role of preconditioning exposure to CNS-penetrating agents?

F. Russo, F. Frigeri, M. Arcamone, 2009, Bone Marrow Transplantation.

Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey

R. Fanin, F. Gherlinzoni, P. Galieni, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma

E. Iannitto, F. Russo, A. Chiara, 2009, Cancer Chemotherapy and Pharmacology.

A phase II study of dose‐dense and dose‐intense ABVD (ABVDDD‐DI) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma

F. Ionna, F. Russo, S. Lastoria, 2014, British journal of haematology.

Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as First-Line Treatment In High-Risk Peripheral T-Cell/NK Lymphomas: A Phase II Trial.

F. Russo, E. Morelli, F. Frigeri, 2010 .

Post-exposure prophylaxis with sotrovimab for Omicron (B.1.1.529) SARS-CoV-2 variant during the aplastic phase of autologous stem cell transplantation

P. Maiolino, N. Coppola, A. Pinto, 2022, Infectious agents and cancer.

RD‐CODOX‐M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B‐cell lymphoma

M. Saggese, F. Russo, A. De Chiara, 2012, British journal of haematology.